Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Phase 1 Active not recruiting 145 enrolled Daiichi Sankyo Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.

Timeline

Start: 2020-09-15
Primary completion: 2024-04-14
Completion: 2026-12-31

Publications

Levy B, Paz-Ares L, Lin CC, Herbert S, Yang TY, Tolcher A, Lou Y, Zenke Y, Cortinovis D, Felip E, Domine M, Leventakos K, Calvo E, Horiike A, Pan E, Basak P, Lin D, Gu W, Chiaverelli R, Chisamore MJ, Goto Y. Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial. J Thorac Oncol. 2026 Mar 21:103688. doi: 10.1016/j.jtho.2026.103688. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Subject	Datopotamab deruxtecan	Monoclonal antibody	4 mg/kg	Intravenous
Subject	Datopotamab deruxtecan	Monoclonal antibody	6 mg/kg	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Summary

Timeline

Publications

Drugs

Indications